Non-traditional immunogens and their application to immunotherapy

Current Opinion in Molecular Therapeutics

Volumn 10, Issue 1, 2008, Pages 62-67

  Chatterjee, M ^a   Tainsky, M A ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

Differential immunoscreening; Immunotherapy; Mimotope; Non traditional epitope; Phage display; SEREX; Tumor associated antigen

Indexed keywords

CD146 ANTIGEN; EPITOPE; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CD8+ T LYMPHOCYTE; CYTOTOXICITY; DNA LIBRARY; HUMAN; IMMUNE RESPONSE; KARYOTYPE; NONHUMAN; OPEN READING FRAME; PHAGE DISPLAY; REVIEW; SEQUENCE HOMOLOGY; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIGENS, NEOPLASM; EPITOPES; HUMANS; IMMUNOTHERAPY; NEOPLASMS;

MUS;

EID: 38649119493     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Lengauer C, Kinzler KW, Vogelstein B: Genetic instabilities in human cancers. Nature (1998) 396(6712):643-649.
2. Velders MP, Nieland JD, Rudolf MP, Loviscek K, Weijzen S, de Visser KE, Macedo MF, Carbone M, Kast WM: Identification of peptides for immunotherapy of cancer. It is worth the effort. Crit Rev Immunol (1998) 18(1-2):7-27.
3. Engelhard VH: Direct identification of tumor-associated peptide antigens. Springer Semin Immunopathol (1996) 18(2):171-183.
4. Boon T: Toward a genetic analysis of tumor rejection antigens. Adv Cancer Res (1992) 58:177-210.
5. Kern F, Surel IP, Brock C, Freistedt B, Radtke H, Scheffold A, Blasczyk R, Reinke P, Schneider-Mergener J, Radbruch A, Walden P, Volk HD: T-cell epitope mapping by flow cytometry. Nat Med (1998) 4(8):975-978.
6. Townsend AR, Rothbard J, Gotch FM, Bahadur G, Wraith D, McMichael AJ: The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell (1986) 44(6):959-968.
7. Sahin U, Türeci O, Schmitt H, Cochlovius B, Johannes T, Schmits R, Stenner F, Luo G, Schobert I, Pfreundschuh M: Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA (1995) 92(25):11810-11813. •• The development of systematic tumor antigen cloning technology is described.
8. Stockert E, Jäger E, Chen YT, Scanlan MJ, Gout I, Karbach J, Arand M, Knuth A, Old LJ: A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med (1998) 187(8):1349-1354.
9. Forti S, Scanlan MJ, Invernizzi A, Castiglioni F, Pupa S, Agresti R, Fontanelli R, Morelli D, Old LJ, Pupa SM, Ménard S: Identification of breast cancer-restricted antigens by antibody screening of SKBR3 cDNA library using a preselected patient's serum. Breast Cancer Res Treat (2002) 73(3):245-256.
10. Qian F, Odunsi K, Blatt LM, Scanlan MJ, Mannan M, Shah N, Montgomery J, Haddad F, Taylor M: Tumor associated antigen recognition by autologous serum in patients with breast cancer. Int J Mol Med (2005) 15(1):137-144.
11. Monji M, Senju S, Nakatsura T, Yamada K, Sawatsubashi M, Inokuchi A, Nishimura Y: Head and neck cancer antigens recognized by the humoral immune system. Biochem Biophys Res Commun (2002) 294(3):734-741.
12. Scanlan MJ, Gordan JD, Williamson B, Stockert E, Bander NH, Jongeneel V, Gure AO, Jäger D, Jäger E, Knuth A, Chen YT, Old LJ: Antigens recognized by autologous antibody in patients with renal-cell carcinoma. Int J Cancer (1999) 83(4):456-464.
13. Mollick JA, Hodi FS, Soiffer RJ, Nadler LM, Dranoff G: MUC1-like tandem repeat proteins are broadly immunogenic in cancer patients. Cancer Immun (2003) 3:3.
14. Van Regenmortel MHV: Molecular dissection of protein antigens and the prediction of epitopes. In: Synthetic Peptides as Antigens. Van Regenmortel MHV, Muller S (Eds), Elsevier Science BV, Amsterdam, the Netherlands (1999):1-78.
15. Meloen RH, Puijk WC, Slootstra JW: Mimotopes: Realization of an unlikely concept. J Mol Recognit (2000) 13(6):352-359.
16. Oldenburg KR, Loganathan D, Goldstein IJ, Schultz PG, Gallop MA: Peptide ligands for a sugar-binding protein isolated from a random peptide library. Proc Natl Acad Sci USA (1992) 89(12):5393-5397.
17. Hoess R, Brinkmann U, Handel T, Pastan I: Identification of a peptide which binds to the carbohydrate-specific monoclonal antibody B3. Gene (1993) 128(1):43-49.
18. Murai H, Hara S, Ikenaka T, Goto A, Arai M, Murao S: Amino acid sequence of protein α-amylase inhibitor from Streptomyces griseosporeus YM-25. J Biochem (Tokyo) (1985) 97(4):1129-1133.
19. Sun Y, Fong KY, Chung MC, Yao ZJ: Peptide mimicking antigenic and immunogenic epitope of double-stranded DNA in systemic lupus erythematosus. Int Immunol (2001) 13(2):223-232.
20. Sharav T, Wiesmuller KH, Walden P: Mimotope vaccines for cancer immunotherapy. Vaccine (2007) 25(16):3032-3037.
21. Motti C, Nuzzo M, Meola A, Galfré G, Felici F, Cortese R, Nicosia A, Monaci P: Recognition by human sera and immunogenicity of HBsAg mimotopes selected from an M13 phage display library. Gene (1994) 146(2):191-198.
22. Chatterjee M, Mohapatra S, Ionan A, Bawa G, Ali-Fehmi R, Wang X, Nowak J, Ye B, Nahhas FA, Lu K, Witkin SS et al: Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays. Cancer Res (2006) 66(2):1181-1190.
23. Chatterjee M, Draghici S, Tainsky MA: Immunotheranostics: Breaking tolerance in immunotherapy using tumor autoantigens identified on protein microarrays. Curr Opin Drug Discovery Dev (2006) 9(3):380-385. •• An excellent review on the identification of different tumor antigens and their utility for personalized immunotherapy.
24. Draghici S, Chatterjee M, Tainsky MA: Epitomics: Serum screening for the early detection of cancer on microarrays using complex panels of tumor antigens. Expert Rev Mol Diagn (2005) 5(5): 735-743. •• A novel cloning and bioinformatics analytical technology, comprising panels of tumor antigens on protein microarrays is described.
25. Boon T, Van Pel A: T cell-recognized antigenic peptides derived from the cellular genome are not protein degradation products but can be generated directly by transcription and translation of short subgenic regions. A hypothesis. Immunogenetics (1989) 29(2):75-79. • The mechanism of mimotope generation from short subgenic regions, termed peptones, is described.
26. Guilloux Y, Lucas S, Brichard VG, Van Pel A, Viret C, De Plaen E, Brasseur F, Lethé B, Jotereau F, Boon T: A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene. J Exp Med (1996) 183(3):1173-1183.
27. Robbins PF, El-Gamil M, Li YF, Fitzgerald EB, Kawakami Y, Rosenberg SA: The intronic region of an incompletely spliced gp100 gene transcript encodes an epitope recognized by melanoma-reactive tumor-infiltrating lymphocytes. J Immunol (1997) 159(1):303-308.
28. Coulie PG, Lehmann F, Lethe B, Herman J, Lurquin C, Andrawiss M, Boon T: A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc Natl Acad Sci USA (1995) 92(17):7976-7980.
29. Wang RF, Wang X, Rosenberg SA: Identification of a novel major histocompatibility complex class II-restricted tumor antigen resulting from a chromosomal rearrangement recognized by CD4+ T cells. J Exp Med (1999) 189(10):1659-1668.
30. Linnebacher M, Gebert J, Rudy W, Woerner S, Yuan YP, Bork P, von Knebel Doeberitz M: Frameshift peptide-derived T-cell epitopes: A source of novel tumor-specific antigens. Int J Cancer (2001) 93(1):6-11.
31. Wang RF, Johnston SL, Zeng G, Topalian SL, Schwartzentruber DJ, Rosenberg SA: A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames. J Immunol (1998) 161(7):3598-3606. •• The generation of antigenic peptides capable of activating CTLs from both normal and alternative open reading frames of the NY-ESO-1 gene is described.
32. Chen YT, Scanlan MJ, Sahin U, Tureci O, Gure AO, Tsang S, Williamson B, Stockert E, Pfreundschuh M, Old LJ: A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA (1997) 94(5):1914-1918.
33. Slager EH, Borghi M, van der Minne CE, Aarnoudse CA, Havenga MJ, Schrier PI, Osanto S, Griffioen M: CD4+ Th2 cell recognition of HLA-DR-restricted epitopes derived from CAMEL: A tumor antigen translated in an alternative open reading frame. J Immunol (2003) 170(3):1490-1497. •• The identification of CD4+ epitopes of CAMEL, a tumor antigen and a product of translation from an alternative reading frame of LAGE-1, is described.
34. Wang RF, Parkhurst MR, Kawakami Y, Robbins PF, Rosenberg SA: Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen. J Exp Med (1996) 183(3):1131-1140.
35. Ronsin C, Chung-Scott V, Poullion I, Aknouche N, Gaudin C, Triebel F: A non-AUG-defined alternative open reading frame of the intestinal carboxyl esterase mRNA generates an epitope recognized by renal cell carcinoma-reactive tumor-infiltrating lymphocytes in situ. J Immunol (1999) 163(1):483-490.
36. Kozak M: Determinants of translational fidelity and efficiency in vertebrate mRNAs. Biochimie (1994) 76(9):815-821.
37. Abastado JP, Miller PF, Jackson BM, Hinnebusch AG: Suppression of ribosomal reinitiation at upstream open reading frames in amino acid-starved cells forms the basis for GCN4 translational control. Mol Cell Biol (1991) 11(1):486-496.
38. Weiss RB, Dunn DM, Atkins JF, Gesteland RF: Slippery runs, shifty stops, backward steps, and forward hops: -2, -1, +1, +2, +5, and +6 ribosomal frameshifting. Cold Spring Harb Symp Quant Biol (1987) 52:687-693.
39. Bonetti B, Fu L, Moon J, Bedwell DM: The efficiency of translation termination is determined by a synergistic interplay between upstream and downstream sequences in Saccharomyces cerevisiae. J Mol Biol (1995) 251(3):334-345.
40. Rammensee HG: Chemistry of peptides associated with MHC class I and class II molecules. Curr Opin Immunol (1995) 7(1): 85-96.
41. Linnemann T, Tumenjargal S, Gellrich S, Wiesmüller K, Kaltoft K, Sterry W, Walden P: Mimotopes for tumor-specific T lymphocytes in human cancer determined with combinatorial peptide libraries. Eur J Immunol (2001) 31(1):156-165. •• The identification of mimotopes that possess the MHC binding motif for T-cell activation as well as in vitro studies to determine the cytolytic activity and specificity of mimotopes for CD8+ T-cells in patients with cutaneous T-cell lymphoma, are described.
42. Hiemstra HS, Duinkerken G, Benckhuijsen WE, Amons R, de Vries RR, Roep BO, Drijfhout JW: The identification of CD4+ T cell epitopes with dedicated synthetic peptide libraries. Proc Natl Acad Sci USA (1997) 94(19):10313-10318.
43. Kruisbeek AM, Amsen D: Mechanisms underlying T-cell tolerance. Curr Opin Immunol (1996) 8(2):233-244.
44. De Magistris MT, Alexander J, Coggeshall M, Altman A, Gaeta FC, Grey HM, Sette A: Antigen analog-major histocompatibility complexes act as antagonists of the T cell receptor. Cell (1992) 68(4):625-634.
45. Sloan-Lancaster J, Evavold BD, Allen PM: Induction of T-cell anergy by altered T-cell-receptor ligand on live antigen-presenting cells. Nature (1993) 363(6425):156-159.
46. Olson JK, Ludovic CJ, Miller SD: Innate and adaptive immune requirements for induction of autoimmune demyelinating disease by molecular mimicry. Mol Immunol (2004) 40 (14-15):1103-1108.
47. Stephen CW, Helminen P, Lane DP: Characterisation of epitopes on human p53 using phage-displayed peptide libraries: Insights into antibody-peptide interactions. J Mol Biol (1995) 248(1): 58-78.
48. Folgori A, Tafi R, Meola A, Felici F, Galfré G, Cortese R, Monaci P, Nicosia A: A general strategy to identify mimotopes of pathological antigens using only random peptide libraries and human sera. EMBO J (1994) 13(9):2236-2243. •• Identification of mimotopes of human HBV envelope protein by peptide phage display library screens using serum from HBsAg-immunized individuals is described.
49. Vaisman N, Nissim A, Klapper LN, Tirosh B, Yarden Y, Sela M: Specific inhibition of the reaction between a tumor-inhibitory antibody and the ErbB-2 receptor by a mimotope derived from a phage display library. Immunol Lett (2000) 75(1):61-67. •• Isolation of mimotopes of ErbB-2 by the peptide phage display library screens with mAbs directed toward ErbB-2 is described.
50. Moreau V, Granier C, Villard S, Laune D, Molina F: Discontinuous epitope prediction based on mimotope analysis. Bioinformatics (2006) 22(9):1088-1095.
51. Mayrose I, Shlomi T, Rubinstein ND, Gershoni JM, Ruppin E, Sharan R, Pupko T: Epitope mapping using combinatorial phage-display libraries: A graph-based algorithm. Nucleic Acids Res (2007) 35(1):69-78.
52. Gorelik L, Flavell RA: Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells. Nat Med (2001) 7(10):1118-1122.
53. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S: Escape of human solid tumors from T-cell recognition: Molecular mechanisms and functional significance. Adv Immunol (2000) 74:181-273. •• An excellent review of different mechanisms by which tumors escape immune responses in cancer patients.
54. Kaklamanis L, Leek R, Koukourakis M, Gatter KC, Harris AL: Loss of transporter in antigen processing 1 transport protein and major histocompatibility complex class I molecules in metastatic versus primary breast cancer. Cancer Res (1995) 55(22):5191-5194.
55. Ferrone S, Marincola FM: Loss of HLA class I antigens by melanoma cells: Molecular mechanisms, functional significance and clinical relevance. Immunol Today (1995) 16(10):487-494.
56. Wojtowicz-Praga S: Reversal of tumor-induced immunosuppression: A new approach to cancer therapy. J Immunother (1997) 20(3):165-177.
57. Novellino L, Castelli C, Parmiani G: A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother (2005) 54(3):187-207.
58. Gundlach BR, Wiesmüller KH, Junt T, Kienle S, Jung G, Walden P: Specificity and degeneracy of minor histocompatibility antigen-specific MHC-restricted CTL. J Immunol (1996) 156(10):3645-3651.
59. Valmori D, Fonteneau JF, Valitutti S, Gervois N, Dunbar R, Liénard D, Rimoldi D, Cerundolo V, Jotereau F, Cerottini JC, Speiser DE, Romero P: Optimal activation of tumor-reactive T cells by selected antigenic peptide analogues. Int Immunol (1999) 11(12):1971-1980.
60. Slansky JE, Rattis FM, Boyd LF, Fahmy T, Jaffee EM, Schneck JP, Margulies DH, Pardoll DM: Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. Immunity (2000) 13(4):529-538.
61. Tumenjargal S, Gellrich S, Linnemann T, Muche JM, Lukowsky A, Audring H, Wiesmüller KH, Sterry W, Walden P: Anti-tumor immune responses and tumor regression induced with mimotopes of a tumor-associated T-cell epitope. Eur J Immunol (2003) 33(11):3175-3185. •• This study describes clinical trials in which mimotopes were used as essential targets for cancer vaccines.
62. Hafner C, Wagner S, Jasinska J, Allwardt D, Scheiner O, Wolff K, Pehamberger H, Wiedermann U, Breiteneder H: Epitope-specific antibody response to Mel-CAM induced by mimotope immunization. J Invest Dermatol (2005) 124(1):125-131.
63. Kieber-Emmons T, Luo P, Qiu J, Chang TY, O I, Blaszczyk-Thurin M, Steplewski Z: Vaccination with carbohydrate peptide mimotopes promotes anti-tumor responses. Nat Biotechnol (1999) 17(7):660-665.
64. Wagner S, Hafner C, Allwardt D, Jasinska J, Ferrone S, Zielinski CC, Scheiner O, Wiedermann U, Pehamberger H, Breiteneder H: Vaccination with a human high molecular weight melanoma-associated antigen mimotope induces a humoral response inhibiting melanoma cell growth in vitro. J Immunol (2005) 174(2):976-982.